USFDA Completes Inspection of Jubilant HollisterStier Contract Manufacturing Facility in Spokane, WA

USFDA Completes Inspection of Jubilant HollisterStier Contract Manufacturing Facility in Spokane, WA​

Jubilant Pharmova Limited has provided details regarding the completion of an inspection conducted by the United States Food and Drug Administration (USFDA) at its subsidiary's contract manufacturing facility. The facility, operated by Jubilant HollisterStier LLC (JHS), is located in Spokane, Washington, U.S.A.

The USFDA concluded the inspection on June 17, 2026. A total of eight observations were issued by the agency, all of which were noted to be unrelated to sterility assurance concerns. JHS has committed to a comprehensive response regarding these observations and intends to complete this process within 15 business days.

Jubilant HollisterStier LLC is defined as a leading integrated contract manufacturer specializing in sterile injectables (both liquid and lyophilization) and ophthalmics, including ointments, liquids, and creams. The company provides specialized manufacturing services for the pharmaceutical and biopharmaceutical industries, offering support that spans from process qualifications through commercial release.

JHS operates under Jubilant Pharma Holding Inc., a subsidiary of Jubilant Pharmova Limited in Singapore, which is itself a wholly owned subsidiary of the parent company.

Global Pharmaceutical Operations Context​

The group maintains extensive operations across various therapeutic areas and geographies:

Jubilant Pharmova Limited:

• Engaged in Radiopharma, Allergy Immunotherapy, and Generics businesses.
• Offers Contract Development and Manufacturing (CD&M) of sterile injectables to pharmaceutical and biotech industries.
• Has facilities for CD&M in Spokane, USA, and Montreal, Canada.
• Operates a US FDA approved Active Pharmaceutical Ingredients manufacturing facility in Nanjangud, Karnataka.
• The Radiopharma business involves the manufacturing and supply of radiopharmaceutical products and services across its 45 radiopharmacies in the USA.

Jubilant Pharma Limited (JPL):

• A wholly owned subsidiary of Jubilant Pharmova Limited and is engaged in integrated global pharmaceutical services.
• Manages Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables, and Non-sterile products.
• Has a network of 45 radio-pharmacies in the US and caters to markets including Europe and other geographies.

The parent company, Jubilant Pharmova Limited, maintains a global footprint with approximately 5,500 multicultural employees and is recognized by leading pharmaceutical companies as a 'Partner of Choice.' The company’s businesses include manufacturing and supply of allergic extracts and venom products for various international markets.

JUBLPHARMA Stock Price Movement​

On Thursday, shares of Jubilant Pharmova Limited slipped by 1.76% to settle at ₹973.45. The stock saw a traded volume of 80,486 shares during the session.